GE HealthCare Technologies Inc. (GEHC)

NMS – Real vaqt narxi. Valyuta: USD

62.29

+0.59 (0.96%)

Yopilishda: May 12, 2026, 4:00 PM EDT

62.50

+0.21 (0.34%)

Bozor oldidan: May 13, 2026, 6:10 AM EDT

07.05.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GE HealthCare Technologies Inc. - GEHC

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GE HealthCare Technologies Inc. ("GE HealthCare" or the "Company") (NASDAQ: GEHC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

02.05.2026

Here's Why GE Healthcare Shares Slumped This Week

GE Healthcare's stock dropped 11.3% after Q1 2026 earnings. Rising costs are pressuring margins, leading to lowered EPS guidance.

30.04.2026

GE HealthCare Just Crashed 13% on a Guidance Cut. Here's the Case for Buying the Dip

GE HealthCare (NASDAQ: GEHC | GEHC Price Prediction) currently trades at $59.49, well below the Wall Street consensus price target of $89.74.

30.04.2026

GE HealthCare Q1 2026: Inflation And Execution Risks Weigh On Outlook

GE HealthCare Technologies is rated a hold following 1Q26, reflecting resilient demand but significant near-term margin pressure. GEHC maintains a robust $21.8B backlog and credible innovation pipeline, supporting mid-single-digit revenue growth, yet faces execution risk from lagged pricing actions. Profitability was hit by $250M in inflation headwinds, tariffs, and Patient Care Solutions weakness, leading to a downward revision in adjusted EPS guidance to $4.80–$5.00.

30.04.2026

GE HealthCare: Soft Execution More Than Priced Accordingly

GE HealthCare shares have fallen to $60 after a soft Q1 and guidance cut, now trading at the low end of their post-spin range. Q1 organic growth was 2.9%, below full-year targets, and EBIT margin guidance was trimmed, but valuation multiples have compressed to 12–13x earnings. Despite headwinds—tariffs, supplier issues, and rising costs—GE HealthCare maintains 3–4% organic growth guidance and is integrating the Intelerad acquisition for incremental EBITDA.

29.04.2026

GE HealthCare Technologies Inc. (GEHC) Q1 2026 Earnings Call Transcript

29.04.2026

GEHC Q1 Earnings Miss Estimates, Revenues Beat, Net Margin Declines

GE HealthCare misses Q1 EPS but tops revenue estimates as Imaging, AVS and PDx growth offset PCS weakness; shares slide due to margin pressure.

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GE HealthCare Technologies Inc. - GEHC

29.04.2026

GE HealthCare announces executive team and operational updates to enhance execution, accelerate innovation, and drive growth

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced today a strategic evolution to its operations and executive leadership team to help shape the company's next chapter of growth and better serve patients and customers globally. The changes will also position the company to enhance execution, accelerate innovation, and create efficiencies. These changes are effective immediately. Phil Rackliffe has been appointed President and Chief Executive Officer of Advanced Imaging Solutions (.

29.04.2026

GE HealthCare reports first quarter 2026 financial results

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today reported financial results for the first quarter ended March 31, 2026. GE HealthCare President and CEO Peter Arduini said, “As we start the year, we're pleased with topline performance, which came in at the high end of our expectations. Growth was driven by strong commercial execution in Pharmaceutical Diagnostics, including Flyrcado, Advanced Visualization Solutions, and Imaging, as well as services. We are maintaining our topline gr.

23.04.2026

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents

CHALFONT ST GILES, England--(BUSINESS WIRE)--GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation.

GE HealthCare Technologies Inc. (GEHC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

GE HealthCare Technologies Inc. (GEHC)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GE HealthCare Technologies Inc. - GEHC

Here's Why GE Healthcare Shares Slumped This Week

GE HealthCare Just Crashed 13% on a Guidance Cut. Here's the Case for Buying the Dip

GE HealthCare Q1 2026: Inflation And Execution Risks Weigh On Outlook

GE HealthCare: Soft Execution More Than Priced Accordingly

GE HealthCare Technologies Inc. (GEHC) Q1 2026 Earnings Call Transcript

GEHC Q1 Earnings Miss Estimates, Revenues Beat, Net Margin Declines

Videolar

No Data

Press-relizlar

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GE HealthCare Technologies Inc. - GEHC

GE HealthCare announces executive team and operational updates to enhance execution, accelerate innovation, and drive growth

GE HealthCare reports first quarter 2026 financial results

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GE HealthCare Technologies Inc. - GEHC

Here's Why GE Healthcare Shares Slumped This Week

GE HealthCare Just Crashed 13% on a Guidance Cut. Here's the Case for Buying the Dip

GE HealthCare Q1 2026: Inflation And Execution Risks Weigh On Outlook

GE HealthCare: Soft Execution More Than Priced Accordingly

GE HealthCare Technologies Inc. (GEHC) Q1 2026 Earnings Call Transcript

GEHC Q1 Earnings Miss Estimates, Revenues Beat, Net Margin Declines

Videolar

No Data

Press-relizlar

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GE HealthCare Technologies Inc. - GEHC

GE HealthCare announces executive team and operational updates to enhance execution, accelerate innovation, and drive growth

GE HealthCare reports first quarter 2026 financial results

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents

Search stocks

GE HealthCare Technologies Inc. (GEHC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

GE HealthCare Technologies Inc. (GEHC)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GE HealthCare Technologies Inc. - GEHC

Here's Why GE Healthcare Shares Slumped This Week

GE HealthCare Just Crashed 13% on a Guidance Cut. Here's the Case for Buying the Dip

GE HealthCare Q1 2026: Inflation And Execution Risks Weigh On Outlook

GE HealthCare: Soft Execution More Than Priced Accordingly

GE HealthCare Technologies Inc. (GEHC) Q1 2026 Earnings Call Transcript

GEHC Q1 Earnings Miss Estimates, Revenues Beat, Net Margin Declines

Videolar

No Data

Press-relizlar

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GE HealthCare Technologies Inc. - GEHC

GE HealthCare announces executive team and operational updates to enhance execution, accelerate innovation, and drive growth

GE HealthCare reports first quarter 2026 financial results

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GE HealthCare Technologies Inc. - GEHC

Here's Why GE Healthcare Shares Slumped This Week

GE HealthCare Just Crashed 13% on a Guidance Cut. Here's the Case for Buying the Dip

GE HealthCare Q1 2026: Inflation And Execution Risks Weigh On Outlook

GE HealthCare: Soft Execution More Than Priced Accordingly

GE HealthCare Technologies Inc. (GEHC) Q1 2026 Earnings Call Transcript

GEHC Q1 Earnings Miss Estimates, Revenues Beat, Net Margin Declines

Videolar

No Data

Press-relizlar

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GE HealthCare Technologies Inc. - GEHC

GE HealthCare announces executive team and operational updates to enhance execution, accelerate innovation, and drive growth

GE HealthCare reports first quarter 2026 financial results

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents